Aegis Capital has reiterated a ‘Buy’ rating and price target of $10 on shares of Celldex Therapeutics’ (NASDAQ: CLDX) stock. The news follows the company’s report of business and financial highlights for the fourth quarter and year-ended December 31, 2016. The company reported total revenue of $1.9 million in the fourth quarter of 2016, and full-year revenue of $6.8 million, compared to $1.8 million and $5.5 million for the comparable periods in 2015. The company credited the increase in revenue to its clinical trial collaboration with Bristol-Myers Squibb. The company also provided an update on its pipeline, including the increase in enrollment of its pivotal METRIC study, expected to be complete by the end of September 2017. Top-line results from this study are expected in the second quarter of 2018. The company expects to provide multiple clinical updates in 2017.
For more information visit www.celldex.com
About Celldex Therapeutics, Inc.
Celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. The company’s pipeline includes antibodies, antibody-drug conjugates and other protein-based therapeutics derived from a broad set of complementary technologies which have the ability to engage the human immune system and/or directly inhibit tumors to treat specific types of cancer or other diseases.
NetworkNewsBreak (NNB) provides a rapid summary of corporate news that caught the attention of NetworkNewsWire (NNW). NNB keeps you up-to-date on active US Public Companies complementary to NNW’s broader scope as a provider of news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer